Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
Gearry
Richard B
RB
Irving
Peter M
PM
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001208:Asia; D001315:Australia; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000208:ethnology; D003362:Cost-Benefit Analysis; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000208:ethnology; D004334:Drug Administration Schedule; D016527:Drug Costs; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006297:Health Services Accessibility; D006801:Humans; D000069285:Infliximab; D018579:Patient Selection; D012074:Remission Induction; D012720:Severity of Illness Index; D013997:Time Factors; D017211:Treatment Failure
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D000069285:Infliximab; D000068879:Adalimumab